CENTI

AUG. 9. 2005 1:43PM AVENTIS US PAT DEPT TO: US CENTRALIZED USPTO RECEIVED
CENTRAL FAX CENTER

NO. 7388

AUG 0 9 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduct	on Act of 1995, no nerso	U.U and process to persond to a	S. Patent and T collection of In	frademark Office formation unless	; U.S. DEPARTMENT OF COMMERCE it displays a valid OMB control number.	
		Application Number	1	10/606,424		
TRANSMITTAL FORM		Filing Date	June 26	June 26, 2003		
		First Named Inventor	Florenc	Florence BORDON-PALLIER et al.		
		Art Unit	1624	1624		
(to be used for all correspondence after initial filing)		Examiner Name	BERCH	BERCH, Mark L.		
Total Number of Pages in This Submission 9		Attorney Docket Number	2541 U	2541 US CNT		
ENCLOSURES (Check all that apply)						
Fee Transmittal Form Fee Attached			rawing(s)		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply After Final Aftidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Petition Petition to Convert to a Provisional Application Power of Allorney, Revoca Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Carks	e Address	Prop	eal Communication to TC cal Notice, Brief, Repty Brief) rietary information us Letter r Enclosure(s) (please identify w):	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name AVENTIS PHARMACEUTICALS INC.						
Signature A1 — William						
Printed name Irvitor Nevir						
Date August 09, 2005		Reg. No. 22,6			38	
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below; (USPTO FAX NO. 571-273-6300; Total No. of Pages Transmitted: _9)						
Signature Brain Extensive						
Typed or printed name Brian Pritchett				Date	August 09, 2005	

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the IndMdusl case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG. 9. 2005. 1:43PM,424 AVENTIS US PAT DEPT

Response dated August 9, 2005 Reply to Office action mailed May 6, 2005

RECEIVED **CENTRAL FAX CENTER** AUG 0 9 2005

NO. 7388 P. 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner:

Berch, Mark L.

F. Bordon-Pallier, et al

Art Unit:

1624

Application No.:

10/606,424

Filed:

June 26, 2003

Title:

Novel Purine Derivatives, Preparation

Method and Use as Medicines

I hereby certify that this correspondence is being transmitted by facsimile to the Commissioner of Patents, P.O. Box 1450. Alexandria, VA 22313-1450, 571-273-8300, at , on

August 9, 2005

Printed Name of Person Signing:

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE UNDER 37 C.F.R. §1.111

Sir:

In response to the Office Action mailed May 6, 2005, please consider the amendment and arguments presented for the above-captioned application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Amendments to the Abstract A substitute Abstract appears on page 6 of this paper.

Remarks/Arguments begin on page 8 of this paper.